Safety of oral molnupiravir administration for hospitalized elderly COVID-19 patients aged 80 years old or older

Not Applicable

Completed

• Conditions: Hospitalized elderly with at least one risk factor for Covid-19 disease; Infections and Infestations

• Registration Number: ISRCTN79981540
• Lead Sponsor: Fukushima Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-06-20
• Study Start: 2022-07-15
• Last Update Posted: 5 August 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

1. Over 80 years of age
2. At least one risk factor of: age >60 years, active cancer, chronic kidney disease, chronic obstructive pulmonary disease, obesity defined by a body-mass index (the weight in kilograms divided by the square of the height in meters) =30, serious heart conditions (heart failure, coronary artery disease, or cardiomyopathies), diabetes mellitus, according to the guidance of Food and Drug Administration and World Health Organization (WHO)

Exclusion Criteria

1. The use of dialysis
2. Estimated glomerular filtration rate of 30 ml/minute/1.73 m² or less
3. Pregnancy
4. Neutropenia (neutrophil count of <500 / ml)
5. Platelet count <100,000/microliter
6. Monoclonal antibodies
7. Remdesivir

Study & Design

• Study Type: Observational
• Study Design: Not specified